Two Phase 3 studies have demonstrated that patients can safely switch between adalimumab, a well-known biologic therapy, and ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced new dermatology data ...

Biocon Biologics presents dermatology data at EADV 2024 Congress, showcasing interchangeability and biosimilarity of ...

Kiran Mazumdar-Shaw has reaffirmed that Biocon is not for sale, despite market rumours. The company is focusing on reducing ...

Here’s a quick look at stocks likely to be in focus in today's trade. Vedanta: Metals conglomerate Vedanta Ltd will review ...

Shares of Regeneron Pharmaceuticals, Inc. REGN were down 4.63% after an unfavorable ruling in its lawsuit against Amgen AMGN ...

Biocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its ...

Bangalore: Biocon has announced that the U.S. Food and Drug Administration (US FDA) has concluded a surveillance inspection ...

Piramal Pharma aims to double its revenue to $2 billion by FY30, while tripling its Ebitda, said company Chairperson Nandini ...

Under the terms of this agreement, Biocon will develop and manufacture the products, and Tabuk Pharmaceuticals will hold the ...

Regeneron Pharmaceuticals (REGN) drops 3.5% after judge denies motion to block generic version of Eylea, a blockbuster eye ...

Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports interchangeability between adalimumab and adalimumab-fkjpBiosimilarity between ...